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Malaria is one of the most serious of all 
tropical parasitic diseases: a severe and 
life-threatening form of which in humans 
is cerebral malaria, a complication 
that can occur in malaria caused by 
Plasmodium falciparum. This grave 
complication involves malarial infection 
of the red blood cells that accumulate 
within the very small capillaries that ﬂ  ow 
through the tissues of the brain. Even 
when treated, cerebral malaria has a 
fatality rate of 15% or more.
Numerous studies have pointed 
to a key role of tumor necrosis factor 
(TNF) and related proteins in the 
pathogenesis of cerebral malaria, and a 
clear relationship has been established 
between plasma concentrations of TNF 
and cerebral pathology. In experimental 
cerebral malaria, TNF-beta, now called 
lymphotoxin α (LT), has been shown to 
be a principal mediator of pathogenesis. 
LT and TNF belong to the same family, 
interact with a common receptor, and 
could act together during disease 
progression to effect the pathogenesis, 
according to recent evidence.
Now Georges Grau and colleagues 
describe the anti-inﬂ  ammatory activity 
of a transcriptional inhibitor of TNF, called 
LMP-420, which might offer a new way 
for treating cerebral malaria. The aim 
of their study was to assess the ability 
of LMP-420 to inhibit the in vitro TNF 
and/or LT effects on brain endothelium, 
with particular attention to endothelial 
cell activation, adhesiveness for malarial 
parasites, and vesiculation.
Using an in vitro model of cerebral 
malaria based on human, brain-derived 
endothelial cells (HBEC-5i), they found that 
LMP-420 potently reduced endothelial 
activation, endothelial adhesiveness for 
P. falciparum–parasitized red blood cells, 
and endothelial MP release, three major 
features of cerebral malaria. 
The results provide evidence for a 
dual inhibitory effect of LMP-420 on 
both TNF and LT in an in vitro model of 
cerebral malaria pathogenesis, when 
added either before or simultaneously 
with both cytokines, they said. LMP-420 
also abolished the cytoadherence of 
ICAM-1-speciﬁ  c P. falciparum–parasitized 
red blood cells on these endothelial 
cells. Identical but weaker effects were 
observed when LMP-420 was added 
with LT. LMP-420 also caused a dramatic 
reduction of HBEC-5i vesiculation 
induced by TNF or LT stimulation.
Several molecules inhibiting TNF, 
such as monoclonal antibody to TNF 
or pentoxyfylline, have been tested in 
clinical trials of cerebral malaria but 
failed to improve disease outcome. These 
failures could be explained by the fact 
that LT was recently demonstrated to also 
have a crucial role in the pathogenesis of 
this cerebral syndrome, said the authors.
They conclude that the anti-
inﬂ  ammatory activity of LMP-420 might 
be useful in targeting the wide variety 
of diseases in which TNF and its related 
family members play a role, and could 
represent a novel, stable, and efﬁ  cient 
therapeutic way to improve the outcome 
of patients with cerebral malaria.
However, the authors caution that 
the experimental in vitro results do not 
necessarily predict potential efﬁ  cacy 
in either animal models or humans, 
especially since in their model the LMP-
420 was administered before the disease 
process was established. Nevertheless, 
this avenue is a promising one to explore 
further.
Wassmer SC, Cianciolo GJ, Combes V, 
Grau GE (2005) Inhibition of endothelial 
activation: A new way to treat cerebral 
malaria? DOI: 10.1371/journal.
pmed.0020245
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The role of insulin resistance (IR) in type 2 diabetes, the most 
frequently encountered metabolic disorder in the world, has 
attracted much attention in recent years. Virtually all patients 
with type 2 diabetes have IR, which usually appears some 10–20 
years before the disease itself. Although the existence of the 
relationship between IR and type 2 diabetes is well recognized, 
the underlying mechanisms are poorly understood. A study 
by Kitt Falk Petersen and colleagues provides important new 
information on the underlying pathogenic mechanisms that lead 
to the development of IR.
Recent ﬁ  ndings have suggested that inherited defects in 
mitochondrial oxidative phosphorylation activity might play a 
key role in the development of IR. Studies have demonstrated 
a relationship between dysregulated fatty acid metabolism, 
fat accumulation in muscle cells, and IR in skeletal muscle. This 
fat accumulation appears to interfere with insulin signaling, 
resulting in reduced insulin-stimulated muscle glucose transport 
activity and decreased muscle glycogen synthesis. Magnetic 
resonance spectroscopy (MRS) studies have found reduced basal 
rates of muscle mitochondrial ATP production, associated with 
increased intramyocellular lipid content. Consistent with these 
results, microarray studies have found a coordinated reduction 
in PGC-1á-responsive genes in patients with obesity and type 2 
diabetes and their overweight ﬁ  rst-degree relatives.
Building on these ﬁ  ndings, Petersen and colleagues examined 
insulin-stimulated rates of muscle ATP synthesis and phosphate 
transport, to investigate whether mitochondrial function is 
affected not only in the fasting state but also during insulin 
stimulation and to determine whether inherited defects in 
mitochondrial oxidative phosphorylation activity might be 
responsible for IR. 
Participants in the study were in their late 20s, lean, 
nonsmoking individuals with IR who were offspring of parents 
with type 2 diabetes. The participants were thus selected to be 
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free of other risk factors for IR such as obesity and smoking. Such 
individuals are ideal for examining the earliest metabolic defects 
responsible for the pathogenesis of IR since they have none of 
the confounding factors that are likely to be present in patients 
with type 2 diabetes. A metabolic defect in this group is likely to 
be an early event of genetic origin and, therefore, is potentially 
a primary cause of the later development of diabetes. The 
individuals in the control group were healthy, nonsmoking, and 
matched for age and weight to the individuals in the IR group. 
Insulin was administered using a hyperinsulinemic-euglycemic 
clamp, and rates of mitochondrial phosphorylation activity 
(muscle ATP synthesis) were assessed by MRS. 
Rates of insulin-stimulated glucose uptake were decreased 
by approximately 50% in the individuals with IR compared 
to the controls and were associated with an approximately 
2-fold increase in intramyocellular lipid content. In the control 
individuals, rates of ATP synthesis increased by approximately 
90% during the hyperinsulinemic-euglycemic clamp. In 
contrast, insulin-stimulated rates of muscle mitochondrial ATP 
synthesis increased by only 5% in the individuals with IR. This 
small increase in muscle mitochondrial ATP synthesis in the 
individuals with IR was associated with a severe reduction of 
insulin-stimulated increases in intramyocellular phosphorus 
concentrations. 
The authors say their study provides further evidence that IR in 
skeletal muscle of individuals with IR who are offspring of parents 
with type 2 diabetes may be related to defects in mitochondrial 
dysfunction. Furthermore, there were also severe defects in 
insulin-stimulated phosphate transport into skeletal muscle in 
the individuals with IR, which may be part of the defect leading to 
impaired ATP synthesis in the muscle of these individuals. 
The implications of the study are also discussed in a Perspective 
by Anton Wagenmakers (DOI: 10.1371/journal.pmed.0020289). 
Although he suggests that the defects underlying IR are likely 
also to involve organs other than muscle, he notes the clinical 
relevance of the main ﬁ  nding, which might explain the weight 
maintenance problems that individuals with obesity and IR have. 
Petersen KF, Dufour S, Shulman GI (2005) Decreased insulin-
stimulated ATP synthesis and phosphate transport in muscle of 
insulin-resistant offspring of type 2 diabetic parents. DOI: 10.1371/
journal.pmed.0020233
DOI: 10.1371/journal.pmed.0020292.g001
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Cesarean section can be a life-saving 
technique for both mother and infant; 
however, it is a major abdominal 
operation that poses medical risks to 
a mother’s health, including infections, 
hemorrhage, need for transfusion, injury 
to other organs, anesthetic complications, 
psychological complications, and a 
maternal mortality two to four times 
greater than that for a vaginal birth. The 
World Health Organization (WHO) has 
said that no country can justify having 
a cesarean rate greater than 10%–15%. 
Despite this advice, in the past 20 years, 
cesarean section rates have risen to 
nearly 25% in some countries.
To address rising rates of cesarean 
delivery, health authorities have 
encouraged women with a previous 
cesarean to attempt vaginal birth in 
subsequent pregnancies. However, 
studies have indicated an increased 
risk of serious adverse outcome among 
such women who attempt vaginal 
birth compared with a planned repeat 
cesarean delivery. This is due to a greatly 
increased risk of complications among 
women who attempt vaginal birth but 
ultimately are delivered by emergency 
cesarean section. Consequently, 
researchers have tried to identify 
women at low and high risk of failure 
for an attempted vaginal birth after a 
prior cesarean, but currently there is no 
validated antepartum tool to predict the 
risk of a failed attempt at vaginal birth 
among women with a prior cesarean 
delivery.
Now Gordon Smith and colleagues 
describe the development of a simple, 
validated model to predict the risk of 
emergency cesarean section among 
women attempting vaginal birth after 
a previous cesarean delivery. They also 
try to determine whether women at 
increased risk of cesarean were also 
at increased risk of uterine rupture, 
including catastrophic rupture leading to 
death of the infant. 
The team studied 23,286 women 
with one prior cesarean delivery who 
attempted vaginal birth at or after 40 
weeks of gestation. The population was 
randomly split into two groups, one on 
which the model was developed and the 
second on which it was validated.
The researchers found that the 
following factors were associated with 
emergency cesarean section: increased 
maternal age, lower maternal height, 
male fetus, no previous vaginal birth, 
prostaglandin induction of labor, and 
A Tool to Estimate the Risks of Repeat Cesarean Section
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birth at 41 weeks or 42 weeks gestation 
compared with 40 weeks. In the 
validation group, 36% of the women 
had a low predicted risk of caesarean 
section and 16.5% of women had a 
high predicted risk; 10.9% and 47.7% of 
these women, respectively, were actually 
delivered by caesarean. 
The predicted risk of caesarean was 
also associated with the risk of uterine 
rupture in general, and of uterine 
rupture associated with perinatal death, 
and women who were at low risk of 
emergency cesarean section were also 
at low risk of uterine rupture, including 
catastrophic rupture leading to perinatal 
death—one of the principal concerns 
among women who have had a previous 
cesarean birth.
Despite the strengths of the present 
study, including the very large population 
size, studies using registry-based data 
have the weakness of inconsistent 
deﬁ  nitions, admitted the authors. Also the 
study lacked data on other risk factors 
for emergency cesarean delivery, such as 
body mass index, the indication for the 
previous cesarean section, and whether 
a previous vaginal birth preceded or 
followed the previous cesarean section. 
Nonetheless, the ﬁ  ndings offer a 
validated model for estimating the risk 
of emergency cesarean section among 
women with a prior cesarean delivery 
who attempt vaginal birth. The true 
worth of the model will become clear 
when other researchers test it.
Smith GCS, White IR, Pell JP, Dobbie R 
(2005) Predicting cesarean section and 
uterine rupture among women attempting 
vaginal birth after prior cesarean section. 
DOI: 10.1371/journal.pmed.0020252
Idiopathic pulmonary ﬁ  brosis is a 
chronic progressive scarring disease of the 
lung in which gradually the walls of the 
air sacs of the lungs become replaced by 
ﬁ  brotic tissue. When scarring forms, there 
is an irreversible loss of the tissue’s ability 
to transfer oxygen into the bloodstream.
The disease affects more than 5 million 
people worldwide, of whom 40,000 die 
every year. Misdiagnosis is common 
because the origin and development of 
the disease is not completely understood. 
There are also no effective treatments; 
drugs to treat lung scarring are still in the 
experimental phase, and treatments to 
suppress inﬂ  ammation have no beneﬁ  cial 
effect in most patients.
Although signiﬁ  cant advances have 
been made in the characterization 
of the clinical features of this disease, 
the molecular mechanism in humans 
is still largely unknown. In general, 
pulmonary ﬁ  brosis might be the result 
of an autoimmune disorder, the after 
effects of a viral infection, or a genetic 
condition. Pulmonary ﬁ  brosis also occurs 
after inhalation of some pollutants, 
in association with diseases such as 
scleroderma, rheumatoid arthritis, 
lupus, and sarcoidosis, and after certain 
medications and therapeutic radiation. 
However, the etiology of idiopathic 
pulmonary ﬁ  brosis is presently unknown.
Now Annie Pardo and colleagues 
examine the role of osteopontin, 
which has diverse functions as a cell-
adhesion and migration molecule, in the 
pathogenesis of idiopathic pulmonary 
ﬁ  brosis. Osteopontin is a multifunctional 
cytokine that has been implicated in 
several physiological and pathological 
processes including bone resorption, 
malignant transformation, and metastasis. 
It is also considered a key molecule for 
regulating inﬂ  ammation, cellular immune 
response, and tissue repair, with a unique 
effect on T cell function.
Using oligonucleotide microarrays 
these researchers have previously 
demonstrated that osteopontin is highly 
upregulated in bleomycin-induced lung 
ﬁ  brosis in mice—an animal model of 
pulmonary ﬁ  brosis.
In the current study, they used 
microarrays to analyze gene expression 
patterns in lung samples (13 samples 
from people with idiopathic pulmonary 
ﬁ  brosis and 11 from control individuals). 
They found that osteopontin was the 
most upregulated gene in the lungs 
of patients with idiopathic pulmonary 
ﬁ  brosis, and that it was mainly expressed 
by alveolar epithelial cells.
To better understand the potential local 
proﬁ  brotic effects of osteopontin they 
then studied its effects on lung ﬁ  broblasts 
and alveolar epithelial cells and found 
that osteopontin induced a signiﬁ  cant 
increase in migration and proliferation 
in both ﬁ  broblasts and epithelial cells. 
However, although the effect on ﬁ  broblast 
migration/proliferation was dependent 
mainly on integrins, in epithelial cells 
proliferation was mainly dependent on 
CD44 and migration was dependent on 
CD44 and integrin signaling.
Osteopontin also showed proﬁ  brotic-
relevant effects on molecules involved 
in extracellular matrix remodeling. For 
example, in ﬁ  broblasts osteopontin 
increased TIMP-1 and type I collagen and 
inhibited MMP-1 expression, whereas in 
alveolar epithelial cells it induced MMP-7.
These ﬁ  ndings concur with previous 
studies in experimental tissue ﬁ  brosis 
that have suggested a possible 
proﬁ  brotic role of osteopontin, said the 
authors. For example in kidney ﬁ  brosis, 
osteopontin enhances macrophage 
recruitment and stimulates the 
development of renal scarring after an 
acute ischemic insult; most importantly, 
mice that do not express the gene for 
osteopontin are protected from lung 
ﬁ  brosis induced by the drug bleomycin. 
Altogether the results suggest a 
mechanism to explain most of the 
proﬁ  brotic effects of osteopontin by 
direct effects on ﬁ  broblasts and epithelial 
cells in the lungs. The ﬁ  ndings also 
suggest that the interaction between 
MMP-7 and osteopontin might be 
involved in the progressive nature of 
the disease. Osteopontin is a potential 
target for therapeutic intervention in this 
relentless, incurable disease.
Pardo A, Gibson K, Cisneros J, Richards 
TJ, Yang Y, et al. (2005) Up-Regulation 
and proﬁ  brotic role of osteopontin in 
human idiopathic pulmonary ﬁ  brosis. DOI: 
10.1371/journal.pmed.0020251
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In the US more than 770,000 people are injured or die each 
year in hospitals from adverse drug events (ADEs), which can cost 
a hospital, depending on its size, about US$5.6 million every year, 
excluding ADE-associated costs for malpractice and litigation 
and the personal costs of injuries to patients. Nationally, hospital 
expenses to treat patients who have ADEs during hospital 
admission are enormous: between $1.6 billion and $5.6 billion 
annually. The cost to patients is also high and not just monetary: 
those who have an ADE spend on average 8–12 days longer in 
the hospital than patients who do not have an ADE, and their 
admission costs $16,000 to $24,000 more.
One way for hospitals to tackle the problem of medication 
errors is to install computerized monitoring systems, which can 
reduce ADEs by 28%–95%. Apart from the obvious beneﬁ  ts to 
patients, these systems can save hospitals as much as $500,000 
annually in direct costs. However, despite the potential, fewer 
than 10% of hospitals have implemented such systems.
Less is known about the value of such systems in an outpatient 
setting. Now, Andrew Steele and colleagues from Denver have 
tested a computerized physician order entry (CPOE) system in 
a US hospital’s outpatient clinic. The main purpose of the study 
was to determine the impact of using computerized alerts to 
improve the prescribing of medications in the outpatient setting. 
Studies have shown that 18%–25% of patients might have an 
ADE in the outpatient environment. This study evaluated a CPOE 
system alongside an integrated computer-based clinical-decision 
support system. 
It focused on a very speciﬁ  c type of clinical-decision support 
system: the use of a rules technology to prevent drug–laboratory 
ADEs. The way the system worked was that providers ordered 
medications on a computer and an alert was displayed if a 
relevant drug–laboratory interaction existed. 
Comparisons were made between baseline and post-
intervention periods. Provider ordering behavior was monitored, 
focusing on the number of medication orders not completed 
and the number of rule-associated laboratory test orders 
initiated after alert display. The investigators found that the rule 
processed 16,291 times during the study period on all possible 
medication orders: 7,017 during the pre-intervention period 
(prescribing doctors did not receive alerts) and 9,274 during the 
post-intervention period (prescribing doctors received alerts). 
During the post-intervention period, an alert was displayed for 
11.8% (1,093 out of 9,274) of the times the rule processed, with 
5.6% of alerts being for “missing laboratory values,” 6.0% for 
“abnormal rule-associated laboratory” values, and 0.2% for both 
types of problems. 
Providers did pay attention to the alerts; they increased 
ordering of the rule-associated laboratory test when an alert 
was displayed (39% at baseline versus 51%  post-intervention, p
< 0.001), thus showing that the rules had a signiﬁ  cant ability to 
change the ordering behavior of the provider, said the authors. 
The strongest effect occurred when providers where alerted 
to “missing” laboratory results (42% increase), the investigators 
noted. There was less of an effect on ordering behavior when 
the alert informed the provider of the existence of an abnormal 
laboratory value (23% increase), which may imply that the cutoff 
values for the “abnormal” trigger were set too low, suggested 
the authors.  However, there was only a modest effect on halting 
the ordering of medications, and this was limited to occasions in 
which the alert presented an abnormal laboratory value in which 
case there was almost a doubling in order cessation.
There are limitations to the study. For example, the 
intervention focused on a speciﬁ  c group of drug–laboratory 
interactions and thus the results may not be generalizable 
to other types of interventions. In addition, the setting was 
a single primary-care clinic outpatient setting within a large 
public-health-integrated health-care delivery system, and 
results may be different in other settings such as hospitals and 
private physician ofﬁ  ces. However, changing prescriber practice 
at all is not easy to achieve and this approach thus warrants 
further research.
Steele AW, Eisert S, Witter J, Lyons P, Jones MA, et al. (2005) The 
effect of automated alerts on provider ordering behavior in an 
outpatient setting. DOI: 10.1371/journal.pmed.0020255
Is it Possible to Change Prescribing Habits? 
DOI: 10.1371/journal.pmed.0020328
If breast cancer cells escape from the 
initial tumor site, they often travel to 
axillary lymph nodes (ALNs) in the armpit. 
Surgical removal and biopsy of axillary 
lymph nodes are routinely used to assess 
the stage of a patient’s cancer, and 
prevent cancers that have spread into 
the lymph nodes from further metastasis. 
Because ALN dissections can cause 
uncomfortable chronic arm swelling, they 
are often preceded by a biopsy of the 
sentinel lymph node, the ﬁ  rst node into 
which the tumor tissue drains. If sentinel 
lymph node biopsy reveals evidence 
of metastasis, surgeons then remove 
and dissect the ALNs. Lymph nodes are 
primarily examined for the presence 
of metastatic tumor cells, and, more 
recently, researchers are even searching 
for the presence of isolated tumor cells 
and breast cancer–associated gene 
expression patterns in local nodes. 
In light of increasing evidence that 
the immune system is perturbed both 
locally at the tumor site and systemically 
as the cancer progresses, Peter Lee and 
colleagues set out to study the state of 
the immune system in draining lymph 
nodes. They determined proﬁ  les of CD4 
and CD8 lymphocytes and dendritic 
cells from sentinel node biopsies and 
(nonsentinel) axillary lymph node 
dissections. Their results suggest 
that these immune proﬁ  les harbor 
independent information about the 
likelihood of tumor recurrence. 
The researchers used automated 
high-resolution imaging to determine 
the numbers of CD4 T cells, CD8 T cells, 
and CD1a-positive dendritic cells in 47 
sentinel and 104 axillary nodes from 
77 patients with breast cancer. Five-
year follow-up data were available 
for all patients, and 33 patients had 
disease recurrence within that time. 
The researchers found that sentinel 
and axillary nodes from cancer patients 
(whether the nodes contained tumor 
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cells or were tumor free) contained 
fewer CD4 and CD8 T lymphocytes than 
nodes from cancer-free control patients. 
Dendritic cells were also reduced in 
tumor-positive nodes, but increased in 
tumor-free axillary nodes. 
By dividing the patients into a “training 
set” of 29 individuals and a “test set” of 
48 individuals, the researchers could 
test whether the correlations found in 
the test set could predict disease-free 
survival. They found that axillary node 
CD4 T cell and dendritic cell numbers, 
regardless of tumor status, were 
correlated with disease-free survival, but 
that this was not the case for immune 
parameters in the sentinel nodes (all of 
which were tumor-positive). Moreover, 
in their dataset, the predictive power of 
the immune parameters in the axillary 
nodes was better than that of any 
other characteristics of the patients, 
including pathological parameters such 
as tumor size and extent or size of nodal 
metastases. 
These results suggest that, in patients 
with tumor-positive sentinel nodes, 
immune proﬁ  le data from axillary nodes 
hold additional information on the 
probability of disease recurrence. As the 
authors suggest, these results warrant 
larger prospective studies to test these 
relationships and explore them in more 
detail. Another important open question 
is whether immune proﬁ  le information 
from lymph nodes can predict risk 
of recurrence even in women whose 
cancers are caught at a stage where they 
have not yet spread to any lymph nodes. 
Kohrt HE, Nouri N, Nowels K, Johnson D, 
Holmes S, et al. (2005) Proﬁ  le of immune 
cells in axillary lymph nodes predicts 
disease-free survival in breast cancer. DOI: 
10.1371/journal.pmed.0020284
DOI: 10.1371/journal.pmed.0020324.g001
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